TherapeuticsMD, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
TherapeuticsMD, Inc. (TXMD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $233.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2023-11-14
- TherapeuticsMD, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-09-30 was $233.00K, a 94.59% decline year-over-year.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-06-30 was $437.00K, a 80.31% decline year-over-year.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-03-31 was $483.00K, a 76.58% decline year-over-year.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2022-09-30 was $4.31M, a 41.11% decline year-over-year.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $11.57M, a 36.15% decline from fiscal 2021.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $18.13M, a 69.73% increase from fiscal 2020.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $10.68M, a 0.03% decline from fiscal 2019.
- TherapeuticsMD, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2019 was $10.68M, a 23.37% increase from fiscal 2018.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-09-30 | $233.00K 10-Q · filed 2023-11-14 | $670.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.15M derived: sum of 3 quarters · filed 2023-11-14 | |||
| 2023-06-30 | $437.00K 10-Q · filed 2023-11-14 | $920.00K derived: sum of 2 quarters · filed 2023-11-14 | ||||
| 2023-03-31 | $483.00K 10-Q · filed 2023-11-14 | |||||
| 2022-12-31 | $11.57M 10-K · filed 2023-04-07 | |||||
| 2022-09-30 | $4.31M 10-Q · filed 2023-11-14 | $6.53M derived: sum of 2 quarters · filed 2023-11-14 | $8.59M derived: sum of 3 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $2.22M 10-Q · filed 2023-11-14 | $4.28M derived: sum of 2 quarters · filed 2023-11-14 | ||||
| 2022-03-31 | $2.06M 10-Q · filed 2023-11-14 | |||||
| 2021-12-31 | $18.13M 10-K · filed 2023-04-07 | |||||
| 2021-09-30 | $7.31M 10-Q · filed 2022-11-14 | $9.82M derived: sum of 2 quarters · filed 2022-11-14 | $12.78M derived: sum of 3 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $2.51M 10-Q · filed 2022-11-14 | $5.47M derived: sum of 2 quarters · filed 2022-11-14 | ||||
| 2021-03-31 | $2.96M 10-Q · filed 2022-11-14 | |||||
| 2020-12-31 | $10.68M 10-K · filed 2022-03-23 | $10.68M 10-K · filed 2021-03-04 | ||||
| 2020-09-30 | $3.13M 10-Q · filed 2021-11-12 | $3.13M 10-Q · filed 2020-11-09 | $6.14M derived: sum of 2 quarters · filed 2021-11-12 | $8.50M derived: sum of 3 quarters · filed 2021-11-12 | ||
| 2020-06-30 | $3.00M 10-Q · filed 2021-11-12 | $3.00M 10-Q · filed 2020-08-07 | $5.37M derived: sum of 2 quarters · filed 2021-11-12 | |||
| 2020-03-31 | $2.37M 10-Q · filed 2021-11-12 | $2.37M 10-Q · filed 2020-05-06 | ||||
| 2019-12-31 | $10.68M 10-K · filed 2022-03-23 | $10.68M 10-K · filed 2020-02-24 | ||||
| 2019-09-30 | $2.64M 10-Q · filed 2020-11-09 | $5.27M derived: sum of 2 quarters · filed 2020-11-09 | $7.85M derived: sum of 3 quarters · filed 2020-11-09 | |||
| 2019-06-30 | $2.64M 10-Q · filed 2020-11-09 | $5.21M derived: sum of 2 quarters · filed 2020-11-09 | ||||
| 2019-03-31 | $2.58M 10-Q · filed 2020-11-09 | |||||
| 2018-12-31 | $8.66M 10-K · filed 2021-03-04 | |||||
| 2018-09-30 | $2.26M 10-Q · filed 2019-11-08 | $4.64M derived: sum of 2 quarters · filed 2019-11-08 | $6.39M derived: sum of 3 quarters · filed 2019-11-08 | |||
| 2018-06-30 | $2.38M 10-Q · filed 2019-11-08 | $4.13M derived: sum of 2 quarters · filed 2019-11-08 | ||||
| 2018-03-31 | $1.75M 10-Q · filed 2019-11-08 | |||||
| 2017-12-31 | $6.76M 10-K · filed 2020-02-24 | |||||
| 2016-12-31 | $17.08M 10-K · filed 2019-02-27 | |||||
| 2015-12-31 | $6.78M 10-K · filed 2018-02-23 | |||||
| 2014-12-31 | $4.61M 10-K · filed 2017-02-28 | $4.24M 10-K · filed 2015-03-12 | ||||
| 2013-12-31 | $3.25M 10-K · filed 2016-02-26 | $3.17M 10-K · filed 2015-03-12 | ||||
| 2012-12-31 | $1.83M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |